SCHEMBL3337375

SCHEMBL3337375

O=C(NNc1nc(-c2ccc(-c3ccccc3)cc2)cs1)c1cc2ccccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.61
KDM4E B2RXH2 12/20 0.61
GAA P10253 10/20 0.61
LMNA P02545 9/20 0.61
ALDH1A1 P00352 8/20 0.61
MAPK1 P28482 3/20 0.57
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
HTT P42858 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
BCAT1 P54687 1/20 0.47
SCD O00767 1/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.46
NOD2 Q9HC29 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341337 0.91 MAPT (0.58) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3338690 0.90 RAB9A (0.55) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3343759 0.89 KDM4E (0.67) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3339390 0.84 GAA (0.47) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3338990 0.83 CA12 (0.48) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3344530 0.83 GAA (0.46) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL7894167 0.80 LMNA (0.58) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL3341776 0.80 MAPT (0.89) MAPTKDM4EGAALMNAALDH1A1
SCHEMBL7894108 0.78 ADORA3 (0.66) MAPTKDM4ELMNAALDH1A1MAPK1
SCHEMBL3342095 0.76 CNR2 (0.47) KDM4EGAALMNAALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.